
|Videos|September 29, 2017
Dr. Aggarwal on Androgen Deprivation Therapy for Prostate Cancer
Author(s)Rahul Aggarwal, MD
Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.
Advertisement
Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.
According to Aggarwal, we are moving away from a one-size-fits-all approach for androgen deprivation therapy to one that is adaptive for a patient’s specific disease state. Physicians are focused on the recent data in regards to abiraterone (Zytiga) and AR-targeted therapies.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Extended Pelvic Lymph Node Dissection Improves MFS in High-Grade Prostate Cancer
5




































































